NrCAM is a marker for substrate‐selective activation of ADAM10 in Alzheimer's disease

The metalloprotease ADAM10 is a drug target in Alzheimer's disease, where it cleaves the amyloid precursor protein (APP) and lowers amyloid‐beta. Yet, ADAM10 has additional substrates, which may cause mechanism‐based side effects upon therapeutic ADAM10 activation. However, they may also serve—...

Descripción completa

Detalles Bibliográficos
Autores principales: Brummer, Tobias, Müller, Stephan A, Pan‐Montojo, Francisco, Yoshida, Fumiaki, Fellgiebel, Andreas, Tomita, Taisuke, Endres, Kristina, Lichtenthaler, Stefan F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460357/
https://www.ncbi.nlm.nih.gov/pubmed/30833305
http://dx.doi.org/10.15252/emmm.201809695

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460357/
https://www.ncbi.nlm.nih.gov/pubmed/30833305
http://dx.doi.org/10.15252/emmm.201809695

Ejemplares similares